Determinants of Drug Costs in Hospitalised Patients with Haemophilia: Impact of Recombinant Activated Factor VII

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.21, Iss.10, 2003-01, pp. : 699-707

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Eptacog-alfa [activated recombinant factor VII] is an effective, well-tolerated therapy in haemophilia patients with inhibitors

Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Recombinant activated Factor VII in major surgery and trauma patients: a response

By Zakhary Randa Grob Seremetis Stephanie

Expert Opinion on Drug Safety, Vol. 4, Iss. 5, 2005-09 ,pp. : 813-814

Informa Healthcare

Access to resources Recommend Favorite

The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients

By Wilson Stephen J Bellamy Mark C Giannoudis Peter V

Expert Opinion on Drug Safety, Vol. 4, Iss. 3, 2005-05 ,pp. : 557-570

Informa Healthcare

Access to resources Recommend Favorite

Management of bleeding emergencies: when to use recombinant activated Factor VII

By DeLoughery Thomas G

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 1, 2006-01 ,pp. : 25-34

Informa Healthcare

Access to resources Recommend Favorite

By van den Bemt P.M.L.A.

Drug Safety, Vol. 22, Iss. 4, 2000-04 ,pp. : 321-333

Adis International

Access to resources Recommend Favorite